Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (2016 - 2025)

Editas Medicine (EDIT) has disclosed Shares Outstanding for 11 consecutive years, with $93.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 12.99% to $93.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $93.3 million, a 12.99% increase, with the full-year FY2024 number at $82.7 million, up 1.18% from a year prior.
  • Shares Outstanding was $93.3 million for Q3 2025 at Editas Medicine, up from $87.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $93.3 million in Q3 2025 to a low of $67.5 million in Q1 2021.
  • A 5-year average of $76.6 million and a median of $81.6 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: grew 23.12% in 2021, then increased 0.57% in 2023.
  • Editas Medicine's Shares Outstanding stood at $68.4 million in 2021, then increased by 0.6% to $68.8 million in 2022, then increased by 18.77% to $81.8 million in 2023, then rose by 1.18% to $82.7 million in 2024, then increased by 12.73% to $93.3 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Shares Outstanding are $93.3 million (Q3 2025), $87.4 million (Q2 2025), and $83.7 million (Q1 2025).